Ramírez SKT

Idioma: Español
Referencias bibliográficas: 14
Paginas: 529-532
Archivo PDF: 205.09 Kb.

RESUMEN

El Virus del Papiloma humano (VPH) es altamente prevalente en la población mundial y es el causante de gran morbimortalidad. Actualmente se dispone de 2 vacunas profilácticas para prevenir enfermedades asociadas con VPH como cáncer cervical y verrugas genitales.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Agorastos, T., Chatzigeorgiou, K., Brotherton, J., et al. Safety of human papillomavirus vaccines: A review of the international experience so far. Vaccine27 (2009) 7270–7281

2. Arguedas O. Vacunación contra el virus del papiloma humano en circunstancias especiales. Actualización médica periódica (2010), 1-11

3. Díaz, M. Counseling the patient with HPV disease. Obstet Gynecol Clin N Am 40 (2013) 391–402

4. Fundación INCIENSA. Estudio de la vacuna contra el virus del papiloma humano en Guanacaste. Addendum al Formulario de Consentimiento Informado Escrito. Institutos de Salud de los Estados Unidos, Bethesda, Maryland, Estados Unidos de América. 2009.

5. Gattoc, L; Nair, N & Ault, K. Human Papillomavirus Vaccination. Obstet Gynecol Clin N Am 40, (2013), 177–197.

6. Hariri, S., Markowitz, L., Dunne, E. & et al. Population Impact of HPV Vaccines: Summary of Early Evidence. Journal of Adolescent Health 53, (2013), 679-682.

7. Kohli, M., Lawrence, D. & et al. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)- 16/18 ASO4-adjuvanted vaccine and a human papillomavirus (HPV)- 6/11/16/18 vaccine in Canada. MC Public Health (2012),12:872

8. Ma, B. & Roden, R. Current Status of Human Papillomavirus Vaccines. Journal of the Formosan Medical Association (2010), 109 (7), 481- 483.

9. Malagón T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012;12(10):781–9.

10. Paul, P. & Fabio, A. Literature review of HPV vaccine delivery strategies: Considerations for school- and non-school based immunization program. Vaccine 32 (2014) 320– 326

11. Saslow D., Castle, P., Cox, T. & et al. American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors. A Cancer Journal for clinicians (2007), 7-28.

12. U.S. Department Health and Human Services. FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report, (2010) 59 (20), 626- 629

13. van der Burg S. & Palefsky, J. Human immunodeficiency virus and human papilloma virus - why HPV-induced lesions do not spontaneously resolve and why therapeutic vaccination can be successful. Journal of Translational Medicine (2009), 7: 108-113.

14. Weinstein L., B. E. (2009). Screening and Prevention: Cervical Cancer. Primary Care: Clinics in Office Practice, 36, 559–574